KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...
KalVista granted orphan drug designation for sebetralstat by MHLW
KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...
KalVista Announces Orphan Drug Designation And NDA Submission For Sebetralstat In Japan
KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...
Cantor Fitzgerald Weighs in on KALV FY2026 Earnings
Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of KalVista Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P.
Nasdaq4d
KalVista Announces Orphan Drug Designation And NDA Submission For Sebetralstat In Japan
(RTTNews) - KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has ...
Morningstar5d
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc., is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals ...
Stockhouse4d
KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company ...
Business Wire18d
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted ...
Hosted on MSN18d
TD Cowen Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation
Fintel reports that on January 7, 2025, TD Cowen initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Buy recommendation. Analyst Price Forecast Suggests 224.00% Upside As of ...